KyungDong Pharm home
Prescription Medicines

Tenelitin Tab. 20mg

Product Category
Diabetes treatment
Active Ingredients
teneligliptin
Appearance
Pink round film-coated tablets
Reimbursement Code
648104770
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Teneligliptin hydrochloride hydrate (in-house specification) ----- 25.96mg (20mg as teneligliptin)
- Additives: Magnesium stearate, opadry pink (03B540007), low-substituted hydroxypropyl cellulose, colloidal silicon oxide, D-mannitol

2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve blood sugar control in adult patients with type 2 diabetes.
1. This drug is administered as monotherapy.
2. This drug is administered as combination therapy in the following cases.
- If sufficient blood sugar control cannot be achieved with metformin monotherapy, this drug is administered as a combination therapy.
- If sufficient blood sugar control cannot be achieved with metformin and sulfonylurea combination therapy, this drug is administered as a combination therapy.

3. Dosage and dosage
The recommended dose of this drug for monotherapy or combination therapy is 20 mg once daily.
Can be taken regardless of meal.
When coadministered with sulfonylurea, a reduction in sulfonylurea may be considered to reduce the risk of hypoglycemia.
No dosage or dosage adjustment is necessary in patients with renal impairment.
No dosage or dosage adjustment is necessary in patients with mild to moderate hepatic impairment.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to the main ingredient or other ingredients of this drug
2) Patients with diabetic ketoacidosis, diabetic coma or precoma, and type 1 diabetes (patients who need to quickly control blood sugar levels with intravenous fluids and insulin, so administration of this drug is not appropriate.)
3) Patients with severe infections, pre- and post-surgery, or severe trauma (administration of this drug is not appropriate as blood sugar control is required through insulin injection.)

2. Administer with caution to the following patients.
1) Patients with severe liver dysfunction: There is no clinical experience in patients with severe liver dysfunction.
2) Heart failure: Because administration experience is limited in patients with New York Heart Association (NYHA) functional class I-II heart failure, it should be used with caution in these patients. Because there is no clinical experience in New York Heart Association (NYHA) functional class III-IV patients, the use of this drug is not recommended.
3) Patients taking sulfonylurease or insulin
4) The following patients or conditions (may cause hypoglycemia)
(1) Pituitary dysfunction or adrenal dysfunction
(2) Malnutrition, starvation, irregular meal intake, insufficient meal intake, or weakness
(3) Patients who performed vigorous muscle exercise
(4) Excessive alcohol intake
5) Patients with a past history of abdominal surgery or intestinal obstruction
6) Patients prone to QT interval prolongation (patients with arrhythmia such as severe bradycardia or previous medical history, patients with heart disease such as congestive heart failure, patients with hypokalemia, etc.): There is a risk of side effects such as QT interval prolongation, so it is recommended to avoid administration in patients with QT interval prolongation or history (congenital long QT interval syndrome, etc.), or patients with a history of torsade de pointes.
7) Pancreatitis: Acute pancreatitis was not reported in Japanese and domestic clinical trials, but one case of acute pancreatitis was reported in European clinical trials and acute pancreatitis was reported after marketing in Japan. Therefore, patients should be informed to seek professional diagnosis from a doctor if characteristic symptoms of acute pancreatitis, such as persistent severe abdominal pain and vomiting, appear. If pancreatitis is suspected after starting treatment, administration of teneligliptin and other suspected drugs should be discontinued (see “Serious Adverse Drug Reactions”).

3. Adverse reactions (Tenelia tablets)
(1) Foreign (Japanese) clinical trial results and post-marketing safety information
In a foreign (Japanese) clinical trial, 232 adverse drug reactions (including abnormal clinical test values) occurred in 156 (9.5%) of the total 1,645 people who took this drug for more than 4 weeks. Major adverse drug reactions included hypoglycemia in 43 patients (2.6%) and constipation in 14 patients (0.9%).
1) Serious adverse drug reactions
low blood sugar
When used in combination with other diabetes drugs, hypoglycemia may occur (8.9% when used in combination with glimepiride, 1.5% when used in combination with pioglitazone, 3.8% when used in combination with meglitinides, 1.1% when used in combination with biguanides, and 1.3% when used in combination with α-glucosidase inhibitors). Additionally, there have been reports of hypoglycemia (1.1%) even when other diabetes drugs were not used together. If symptoms of hypoglycemia appear, take appropriate measures, such as consuming foods containing carbohydrates. When used in combination with α-glucosidase inhibitors, glucose must be administered.
Intestinal obstruction (0.1%)
As intestinal obstruction may occur, observe thoroughly. If abnormalities such as severe constipation, abdominal distension, persistent abdominal pain, or vomiting appear, discontinue administration and take appropriate measures.
Liver dysfunction (incidence unknown, post-marketing safety information)
Liver dysfunction (elevated AST (GOT), ALT (GPT), etc.) may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration if suspected.
Interstitial pneumonia (incidence unknown, postmarketing safety information)
Interstitial pneumonia may occur, so if coughing, shortness of breath, fever, or abnormal lung sounds (crepitus) are observed, appropriate tests such as chest X-ray and chest CT should be promptly performed. If interstitial pneumonia is suspected, discontinue administration and take appropriate measures, such as administration of corticosteroids.
Pemphigus vulgaris (incidence unknown, post-marketing safety information)
Pemphigus vulgaris may occur, so if blisters or erosions are observed, consult a dermatologist and take appropriate measures, such as discontinuing administration.
Acute pancreatitis (incidence unknown, post-marketing safety information)
Acute pancreatitis may occur. Patients should be carefully observed, and if abnormalities such as persistent severe abdominal pain and vomiting are observed, administration of this drug should be discontinued and appropriate treatment should be taken (see “Careful administration” section).

2) Other adverse drug reactions
If adverse drug reactions occur, take appropriate measures, such as discontinuing administration.
Table 1. Other adverse drug reactions
*Table: Refer to manual

(2) Domestic clinical trial results
1) Monotherapy
The safety of a total of 142 subjects was analyzed in a randomized, double-blind, parallel group, placebo-controlled, phase 3 clinical trial conducted in Korea.
During the 24 weeks of the clinical trial, the adverse reaction rate was 45.45% (20/44 patients) in the placebo group and 29.59% (29/98 patients) in the this drug group. The adverse reaction rate was 6.82% (3/44 patients) in the placebo group and 1.02% (1/98 patients) in the this medication group. The differences between groups in the incidence of adverse reactions and adverse drug reactions were not statistically significant. The adverse drug reaction was dyslipidemia. As a result of clinical trials, adverse reactions reported at a frequency of 2% or more, which occurred more frequently in patients receiving this drug than in patients receiving placebo, are shown in Table 2.
Table 2. As a result of monotherapy clinical trials of this drug, adverse reactions reported at a frequency of 2% or more occurred more frequently in patients receiving this drug compared to placebo (regardless of the investigator's assessment of causality).
*Table: Refer to manual

2) Metformin combination therapy
The safety of a total of 205 subjects was analyzed in a double-blind, parallel group, randomized, placebo-controlled clinical trial conducted in Korea.
During the 16-week clinical trial period, the adverse reaction rate was 44.9% (31/69 people) in the placebo and metformin combination group and 41.2% (56/136 people) in the placebo and metformin combination group. The adverse reaction rate was 1.4% (1/69 people) in the placebo and metformin combination group and the drug and metformin combination group. It was 3.7% (5/136 people). The differences between groups in the incidence of adverse reactions and adverse drug reactions were not statistically significant. Adverse drug reactions were diarrhea, epigastric pain, hepatic steatosis, liver failure, edema, and rash. As a result of clinical trials, adverse reactions reported at a frequency of 1% or more, which occurred more frequently in patients receiving this drug and metformin than in patients receiving placebo and metformin, are shown in Table 3.
Table 3. As a result of clinical trials of this drug in combination with metformin, adverse reactions reported at a frequency of 1% or more occurred more frequently in patients receiving this drug and metformin than in patients receiving placebo and metformin (regardless of the investigator's assessment of causality).
*Table: Refer to manual

3) Metformin and glimepiride combination therapy
The safety of a total of 200 subjects was analyzed in a multicenter, randomized, double-blind, non-inferiority, active-controlled, phase 3 clinical trial conducted in Korea.
During the 24-week clinical trial period, the adverse reaction rate was 62.24% (61/98 patients) in the active control drug combination group and 61.76% (63/102 patients) in the active control drug combination group, and the adverse reaction rate was 40.82% (40/98 patients) in the active control drug combination group and this drug combination treatment group. It was 45.10% (46/102 people). The differences between groups in the incidence of adverse reactions and adverse drug reactions were not statistically significant. Adverse drug reactions were hypoglycemia, dizziness, tremors, headache, asthenia, hunger, fatigue, facial swelling, diarrhea, indigestion, constipation, nausea, viral upper respiratory infection, shingles, rhinitis, cold sweat, itching, diabetic retinopathy, decreased vision, cough, pulmonary congestion, difficulty breathing, drug overdose, and prostatic hyperplasia. As a result of clinical trials, adverse reactions reported at a frequency of more than 1% occurred more frequently in the group administered with this drug than in the group administered with the active comparator drug, and are listed in Table 4.
Table 4. Results of clinical trials of this drug's combination therapy (metformin and glimepiride). Adverse reactions reported at a frequency of more than 1% occurred more frequently in this drug's combination treatment group compared to the active comparator drug combination group (regardless of the researcher's causality assessment).
*Table: Refer to manual

4) Hypoglycemia confirmed as a result of domestic clinical trials
As a result of the monotherapy clinical trial, among 142 test subjects, only 1 (2.3%) in the placebo group experienced hypoglycemia, and the reported case was classified as a case of suspected hypoglycemia. In the clinical trial results of metformin combination therapy, among 205 test subjects, the subjects who experienced hypoglycemia were 2 (2.9%) in the placebo and metformin combination group and 4 (2.9%) in the drug and metformin combination group, and all were classified as cases of suspected hypoglycemia. In the clinical trial of the combination therapy of metformin and glimepiride, self-blood sugar was measured at least once a day and collected as hypoglycemia until it was reported as ‘asymptomatic hypoglycemia symptoms.’ Among the 200 test subjects, the subjects who experienced hypoglycemia excluding ‘asymptomatic hypoglycemia symptoms’ were 21 (20.59%) in the group administered metformin, glimepiride, and this drug in combination; There were 19 patients (19.39%) in the group that received metformin, glimepiride, and active control drug in combination. When ‘asymptomatic hypoglycemic symptoms’ were included, the test subjects who experienced hypoglycemia were 32 (31.37%) in the group administered metformin, glimepiride and this drug in combination, and 28 (28.57%) in the group administered active control drug in combination. Among the reported hypoglycemias, severe hypoglycemia occurred in one person each in the test and control groups.
(3) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,042 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 6.54% (199/3,042 people, 263 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
* Table: refer to manual

In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
* Table: refer to manual

4. General precautions
1) Co-administration with drugs known to cause hypoglycemia: When this drug is used together with insulin secretion stimulants such as insulin and sulfonylurea, the occurrence of hypoglycemia may increase. When used in combination with sulfonylurea drugs or insulin, a reduction in the amount of sulfonylurea drugs or insulin may be considered to reduce the risk of hypoglycemia. When using this medicine, fully explain to the patient the symptoms of hypoglycemia and how to deal with it.
2) Application is only considered for patients diagnosed with type 2 diabetes. Please note that in addition to diabetes, there are diseases that show diabetes-like symptoms (nephrogenic diabetes, abnormal thyroid function, etc.), such as impaired glucose tolerance and positive urine glucose.
3) Since symptoms of hypoglycemia may occur, be careful when administering to patients who work at heights or drive a car.
4) Severe and disabling joint pain
Severe and disabling arthralgia have been reported in post-marketing studies in patients taking other DPP-4 inhibitors. The onset of symptoms after drug administration varied from 1 day to several years later. Symptoms were alleviated when drug administration was stopped. In some patients, recurrence of symptoms occurred when taking the same drug or a different DPP-4 inhibitor. Consider the DPP-4 inhibitor as the cause of severe arthralgia and, if appropriate, discontinue administration.
5) Bullous pemphigoid
In post-marketing surveillance in patients taking DPP-4 inhibitors, cases of bullous pemphigus requiring hospitalization have been reported. Patients generally recovered with discontinuation of DPP-4 inhibitors and treatment with topical or systemic immunosuppressants. Patients should be advised to immediately report to their doctor if blisters or sores occur while taking this medication. If bullous pemphigus is suspected, this drug should be discontinued and a dermatologist should be consulted for diagnosis and appropriate treatment.

5. Interaction
Teneligliptin is mainly metabolized by CYP3A4 and flavin-containing monooxygenase (FMO1 and FMO3), and the excretion rate of unmetabolized teneligliptin through urine was 14.8-22.1%.
1) Ketoconazole: When ketoconazole, a strong CYP3A4 inhibitor and P-gp inhibitor, was coadministered with 20 mg of teneligliptin, the AUC and Cmax of teneligliptin increased by 1.49-fold and 1.37-fold, respectively.
2) Metformin: When teneligliptin 40mg and metformin were administered together, metformin did not significantly change the pharmacokinetics of teneligliptin. In addition, by co-administering teneligliptin, the AUC of metformin showed a slight increase (geometric least squares mean ratio [90% CI]: 1.209 [1.143∼1.278]), but Cmax did not change. It is thought unlikely that teneligliptin will have a significant effect on the pharmacokinetics of metformin.
3) Sulfonylurea: When teneligliptin 40mg and glimepiride were co-administered, no drug interaction between teneligliptin and glimepiride was confirmed.
4) Taazolidinedione: When teneligliptin 40mg and pioglitazone were co-administered, teneligliptin did not significantly change the pharmacokinetics of pioglitazone and its active metabolites (M-III and M-IV). In addition, the Cmax of teneligliptin showed a slight increase (geometric least squares mean ratio [90% CI]: 1.117 [0.984∼1.266]) by co-administering pioglitazone, but the AUC did not change. There appears to be little effect of coadministration with pioglitazone on the pharmacokinetics of teneligliptin.
5) Like other oral diabetes drugs, the blood sugar lowering effect of teneligliptin can be further increased by drugs that increase the blood sugar lowering effect such as β-blockers, salicylates, and MAO inhibitors, so it should be administered while sufficiently observing the blood sugar level and patient condition.
6) Like other oral diabetes drugs, the blood sugar lowering effect of teneligliptin can be reduced by drugs that reduce the blood sugar lowering effect such as adrenaline, corticosteroids, and thyroid hormones, so it should be administered while sufficiently observing the blood sugar level and patient condition.
7) There is a risk of QT interval prolongation when coadministered with arrhythmia drugs of class IA (e.g., quinidine, procainamide) or group III (e.g., amiodarone, sotalol) that may cause QT interval prolongation.

6. Administration to pregnant and lactating women
1) There are no appropriate clinical trial results for pregnant women, so its use in pregnant women is not recommended. This drug has been observed to transfer to the fetus in non-clinical trials (rats).
2) It is not known whether this drug is secreted into human breast milk, and it was reported to be secreted into breast milk in non-clinical tests (rats). Whether or not to discontinue breast-feeding should be decided after careful consideration of the benefits of this drug administration and breast-feeding.

7. Administration to children
Safety and efficacy in children have not been established (no clinical experience).

8. Administration to elderly people
In general, elderly people often have reduced physiological function, so it is administered while observing the patient's condition.

9. Treatment in case of overdose
There were no cases of overdose in clinical trials conducted domestically and overseas. The highest dose of this drug used in clinical trials is 320mg administered to healthy adults for single administration, and 80mg administered once daily for 7 days for repeated administration to healthy adults. No serious adverse reactions or adverse reactions leading to discontinuation of administration were identified at these doses.
In case of overdose, general symptomatic treatment is administered (e.g., removal of unabsorbed drug from the gastrointestinal tract and clinical monitoring including electrocardiogram), and auxiliary treatment is provided depending on the patient's condition.
In patients with end-stage renal failure, 15.6% of the administered teneligliptin dose was removed during hemodialysis.

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

11. Pharmaceutical equivalence test information
As a result of measuring teneligliptin in the blood of 32 people, one tablet each was orally administered on an empty stomach in a 2×2 crossover study of the test drug Teneritin tablets 20 mg (Teneligliptin hydrochloride hydrate) (KyungDong Pharm Co., Ltd.) and the reference drug Tenellia tablets 20 mg (Teneligliptin hydrobromide hydrate) (Handok Co., Ltd.). When comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
* Table: refer to manual

12. Others
1) For teneligliptin, a reverse mutation test using bacteria, a chromosomal abnormality test using CHL/IU cells, a rat micronucleus test, and an irregular DNA synthesis test in rats were conducted. In the chromosomal abnormality test, an increase in structural abnormalities, which appears to be a secondary change in cytotoxicity, was confirmed, but other tests did not cause abnormal mutations, so there appears to be no risk of genotoxicity.
2) As a result of evaluating carcinogenicity using rats and mice, carcinogenicity was not confirmed even at the dose considered to be the maximum tolerated dose (male rat: 75 mg/kg/day, female rat 100 mg/kg/day, mouse: 600 mg/kg/day). The highest doses evaluated in rats and mice represent 65- and 118-fold greater exposure compared to humans at 40 mg/day. The non-toxic dose for non-neoplastic lesions was 10 mg/kg/day and 60 mg/kg/day in rats and mice, respectively (corresponding to approximately 4 times the exposure of 40 mg per day in humans).
3) In a reproductive toxicity test conducted using rats, the non-toxic dose for male and female fertility and reproductive performance was 70 mg/kg/day and 100 mg/kg/day, respectively, which is 11 to 45 times the exposure amount compared to 40 mg/day administered to the human body. In embryo-fetal developmental toxicity tests conducted using rats and rabbits, no teratogenic findings were confirmed in both species, and the non-toxic dose for developmental toxicity is 30 mg/kg/day, which is approximately 11 and 16 times the exposure to humans administered at 40 mg/day. In tests on prenatal and postnatal development and maternal function conducted using rats, the non-toxic dose was 30 mg/kg/day, which is approximately 11 times the exposure amount compared to 40 mg/day administered to humans.
4) In a foreign clinical trial, teneligliptin 160mg was administered repeatedly for 4 days once a day to healthy adults. At this time, placebo-adjusted mean QTc interval prolongation was observed for each individual up to 9.3 msec (90% CI upper limit 13.0 msec). There is no experience in administering more than 160 mg per day in humans.

13. Information for experts
1) Clinical trial information
Monotherapy
The efficacy and safety of this drug as monotherapy were evaluated in a randomized, double-blind, multicenter, 24-week, placebo-controlled clinical trial involving a total of 142 patients with type 2 diabetes (HbA1c 7% or more and less than 10%) who had poor glycemic control with diet and exercise therapy. After a 2-week, single-blind, placebo run-in period, patients were randomly assigned to receive either 20 mg of this drug or placebo once daily.
After 24 weeks of administering this drug, glycated hemoglobin (HbA1c) in the 20 mg group of this drug decreased statistically significantly compared to the placebo group, and the proportion of patients whose glycated hemoglobin (HbA1c) reached less than 7% was statistically significantly higher than that in the placebo group [see Table 5].
Table 5. Results at 24 weeks of a placebo-controlled, monotherapy clinical trial of this drug in patients with type 2 diabetes.
*Table: Refer to manual
Combination therapy
Additional combination of this drug to metformin monotherapy
In a randomized, double-blind, multicenter, placebo-controlled clinical trial involving a total of 207 patients with type 2 diabetes (HbA1c 7% to less than 10%) who had poor glycemic control with metformin monotherapy (daily dose of 1,000 mg or more for 8 weeks or more), the efficacy and safety of this drug when combined with metformin were evaluated. After a 2-week single-blind, placebo run-in period while continuing metformin treatment, patients were randomly assigned to receive 20 mg of this drug or placebo once daily.
After 16 weeks of treatment with this drug, glycated hemoglobin (HbA1c) in the 20 mg group of this drug decreased statistically significantly compared to the placebo group, and the proportion of patients whose glycated hemoglobin (HbA1c) reached less than 7% was statistically significantly higher than that in the placebo group [see Table 6].
Table 6. 16-week treatment results in a placebo-controlled clinical trial of the addition of this drug to metformin in patients with type 2 diabetes
*Table: Refer to manual
Additional combination of this drug to metformin and glimepiride combination therapy
A randomized, double-blind, multicenter, active drug-controlled (sitagliptin 100 mg) clinical trial involving a total of 201 patients with type 2 diabetes (HbA1c 7% or higher and 11% or lower) who had poor glycemic control with metformin (taken at a daily dose of 1,000 mg or more for more than 8 weeks) and glimepiride (taken at a daily dose of 4 mg or more for more than 8 weeks) was conducted to determine the efficacy and efficacy of this drug. Safety was assessed. Patients were randomly assigned to receive 20 mg of this drug or 100 mg of sitagliptin once daily after a 2-week, single-blind, placebo run-in period while maintaining metformin and glimepiride. After registration in the clinical trial, the dose of glimepiride could be reduced at the discretion of the investigator to prevent or manage hypoglycemia.
After 24 weeks of administration, this drug 20 mg was non-inferior to sitagliptin [see Table 7].
Table 7. Results of 24-week administration in an active drug-controlled clinical trial using this drug in combination with metformin and glimepiride in patients with type 2 diabetes
*Table: Refer to manual

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 1items

No.Product NameDetailsDate of ChangeDownload
1Tenelitin Tab. 20mgPrecautions for use2023.06.14PDFPrecautions for use of teneligliptin tablets 20mg (draft).pdf